Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04626466
Other study ID # 2020-004
Secondary ID 2020-A01108-31
Status Completed
Phase
First received
Last updated
Start date August 3, 2020
Est. completion date January 2, 2024

Study information

Verified date January 2024
Source Institut de cancérologie Strasbourg Europe
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when concomitant chemotherapy is used, volume of bone marrow irradiated is large and dose to the bone marrow is high. There is a lack of prospective studies and comparative trials to customize the constraints according to the presence or absence of chemotherapy and correlated to the patient's bone marrow potential. This multicentric and prospective study conducted by Strasbourg Europe Cancerology Institute aims to evaluate hematological toxicity (anemia, thrombocytopenia, leukopenia) in patients treated with pelvic irradiation for prostate, rectum, anal canal, endometrium, cervix cancer or vaginal cancer. One hundred patients will be included in the study, including patients treated with exclusive radiotherapy, radiochemotherapy, or radiohormonal therapy. The primary objective is to quantify the relationship between acute hematological toxicity and delivered doses and irradiated volumes in pelvic bone marrow for pelvic cancers. Hematological toxicity will be measured by weekly blood count during radiotherapy and at one month and three months after the end of radiotherapy. Secondary endpoints are the evaluation of viral, bacterial and fungal infections during and for three months following radiotherapy, as well as the evaluation of the impact of radiation-induced hematological toxicity on the administration of chemotherapy for the concerned patients. The aim of this study is to improve and optimize radiotherapy if a dose limit or volume constraint is imposed by the results of the study.


Description:

Patients will be identified as potentially eligible for inclusion once radiotherapy has been decided upon at the multidisciplinary consultation meeting. During the radiotherapy consultation, the study will be offered to the patient if they also meet the other inclusion criteria. As soon as the consent is signed and before the first radiotherapy session, a first biological check-up including a blood count and renal function will be performed. This biological investigation will serve as a reference. During the dosimetric computer-tomography scan for radiotherapy, bony structures will be delineated, iliac bones, lower pelvis, femoral heads, lumbosacral spine and entire pelvis. Dosimetry will be performed in the same way whether patients are included in the study or not, they will receive between 25Gy in 5 fractions and 78Gy in 39 fractions, depending on the primary tumor. The dose volume histograms will be received. During treatment, patients will have a weekly blood test starting from the second week of treatment. At one months and three months after the end of the radiotherapy, patients will be seen in consultation and will also have a blood test.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 2, 2024
Est. primary completion date January 2, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria : Inclusion Criteria: - Patients must be = 18 years old and < 80 years old - Performance Status 0 to 2 - Histologically-confirmed diagnosis of : prostate cancer ; cervical cancer ; vaginal cancer ; endometrial cancer ; middle or low rectal cancer ; anal duct carcinoma - At inclusion, patients must have : Haemoglobin > 10 g/dL ; Leucocytes 4.0-11.0 g/L ; Neutrophils 1.5-7.7 g/L ; Platelets 150-400 g/L - Signed informed consent from the patient Exclusion Criteria: - History of haematologic disorders, leucopathia or imune system diseases - At inclusion, patients must not have : Haemoglobin < 10 g/dL or > 18 g/dL (men) > 16 g/dL (women) ; Leucocytes < 4.0 or > 11.0 g/L ; Neutrophils < 1.5 or > 7.7 g/L ; Platelets < 150 or > 400 g/L - Patients previously treated with radiation therapy or with chemotherapy - Patients with metastatic cancer - Patients presenting tumor classified histologically as sarcomatoid - Patients placed under judicial protection, guardianship, or supervision - Women that are pregnant or breast-feeding

Study Design


Intervention

Other:
Biological investigations
(complete blood count, platelet count, renal function evaluation)

Locations

Country Name City State
France CHRU Jean Minjoz Besançon
France Centre Georges François Leclerc Dijon
France Institut de Cancerologie Strasbourg Europe Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
Institut de cancérologie Strasbourg Europe

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of acute haematological toxicity according to CTCAE v5.0 Haemoglobin
Platelets
Neutrophils
Lymphocytes
throughout radiotherapy treatment
Primary Assessment of acute haematological toxicity according to CTCAE v5.0 Haemoglobin
Platelets
Neutrophils
Lymphocytes
1 month after the end of radiotherapy
Primary Assessment of acute haematological toxicity according to CTCAE v5.0 Haemoglobin
Platelets
Neutrophils
Lymphocytes
3 months after the end of radiotherapy
Secondary Number of patients with clinical signs of viral, bacterial, or fungal infections according to CTCAE v5.0 throughout treatment, at 1 and 3 months
Secondary Number of patients undergoing definitive and transient discontinuations of concomitant chemotherapy. throughout treatment, at 1 and 3 months
Secondary Number of patients who required a reduction in chemotherapy dose. throughout treatment, at 1 and 3 months
Secondary Cumulative doses and theoretical doses of chemotherapy. throughout treatment, at 1 and 3 months
Secondary Number of patients undergoing definitive withdrawal or transitory stops of the entire treatment. throughout treatment, at 1 and 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT03212742 - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Phase 1/Phase 2
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Withdrawn NCT02542137 - Abscopal Effect for Metastatic Small Cell Lung Cancer Phase 2
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01168479 - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer Phase 3
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Completed NCT03280719 - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT05514327 - A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL N/A
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Recruiting NCT03370926 - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Active, not recruiting NCT02428049 - Radiation Pneumonitis After SBRT for NSCLC
Recruiting NCT04923620 - Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Active, not recruiting NCT05371795 - Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device N/A
Recruiting NCT03210428 - Quantitative MR Imaging in Locally Advanced Cervical Cancer